Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
BörsenkürzelVCYT
Name des UnternehmensVeracyte Inc
IPO-datumOct 30, 2013
CEOMr. Marc A. Stapley
Anzahl der mitarbeiter824
WertpapierartOrdinary Share
GeschäftsjahresendeOct 30
Addresse6000 Shoreline Court, Suite 300
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94080
Telefon16502436300
Websitehttps://www.veracyte.com/
BörsenkürzelVCYT
IPO-datumOct 30, 2013
CEOMr. Marc A. Stapley
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten